SNO Highlights New E3F05 Glioma Trial Findings

Lead investigator David Schiff, MD (pictured), presented a new molecular analysis of the phase 3 E3F05 trial (for adults with grade 2 glioma) at the Society of Neuro-Oncology (SNO) 2025 Annual Meeting in November. Trial investigators performed methylation profiling to determine IDH mutational status in enrolled patients. The results showed that adding temozolomide to radiotherapy improved overall survival (OS) and progression-free survival compared to radiotherapy alone in patients with IDH-mutant low-grade glioma. The findings also showed a significant OS benefit, especially in IDH-mutant astrocytomas. Learn more in this OncLive video interview.

MyeloMATCH at ASH: First Results and Trials in Process

Researchers presented the first results from MyeloMATCH at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in early December. MyeloMATCH is a National Cancer Institute (NCI)-supported portfolio of precision medicine trials for people with myeloid malignancies, particularly acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It opened for patient enrollment across the United States and Canada in 2024. Rapid molecular testing is performed at diagnosis to assign patients to genomically guided substudies. This year’s presentations at ASH included an oral report on fusion detection in the first 400 participants, as well as five posters. The screening protocol is coordinated by the SWOG Cancer Research Network (SWOG), with treatment trials led by the Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), and SWOG. Learn more.

Reminder: Revised NIH Public Access Policy

As outlined in last month’s newsletter, the National Institutes of Health (NIH) has updated its public-access policy: effective July 1, 2025, all peer-reviewed manuscripts funded by NIH and accepted for publication must be submitted to PubMed Central (PMC) and made publicly available immediately—with no embargo period or delay. ECOG-ACRIN researchers therefore need to confirm that respective journals allow immediate PMC posting, include the required NIH funding acknowledgments, and ensure the article is deposited either by the publisher or via the NIH Manuscript Submission system (NIHMS) promptly. The change is meant to enhance equitable access and accelerate scientific discovery by making taxpayer-funded research available to patients and the public in a timely manner. Read the full article for additional details.

Fall Group Meeting Session Recordings Still Available

Did you miss the Fall 2025 Group Meeting? Did you attend but wish to go back and access sessions? If you are an ECOG-ACRIN member, you can catch up on important study updates and trainings by viewing our library of session recordings from the Fall 2025 Group Meeting. These are available for both attendees and those who missed the meeting. Attendees can simply visit the Attendee Hub Website and log in with the information provided during registration. Everyone else should first register for the meeting and then visit the Attendee Hub to view session recordings on demand.

After registration, users should go to the Attendee Hub and log in with the information they provided. Navigate to ‘Schedule,’ and then select ‘On Demand’ from the dropdown list. Note: The Attendee Hub Website will expire 90 days following the meeting (mid-January 2026).

In the coming weeks, we will also post select session recordings and resources from the Fall Group Meeting on the members’ section of the ECOG-ACRIN website. These materials will be available to anyone with member login credentials, regardless of meeting attendance.

ASCO 2026 Abstract Submissions Now Open

The American Society of Clinical Oncology (ASCO) is now accepting abstract submissions for the 2026 ASCO Annual Meeting. The deadline for submission is Tuesday, January 27, 2026, at 11:59 PM ET. More information is on the ASCO website. Please notify publications@ecog-acrin.org immediately if you plan to submit an abstract to ASCO.

All draft abstracts using ECOG-ACRIN study data must be submitted to the ECOG-ACRIN publications team (publications@ecog-acrin.org) by Tuesday, January 13, 2026. This includes regular abstracts, trial-in-progress abstracts and late-breaking abstract placeholders. This deadline is firm, and necessary to ensure sufficient time for ECOG-ACRIN to prepare/review the authorship line and for a courtesy review by NCI and industry collaborators, if applicable.

For questions regarding ECOG-ACRIN publication procedures, please contact the ECOG-ACRIN publications team. ECOG-ACRIN publication and authorship guidelines are available on the member section of the ECOG-ACRIN website.